Online inquiry

IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8908MR)

This product GTTS-WQ8908MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IGHE gene. The antibody can be applied in Chronic idiopathic urticaria research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NC_000014.9
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3497
UniProt ID P01854
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ8908MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2180MR IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ALT-803
GTTS-WQ9442MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IPH-2201
GTTS-WQ4991MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA C4G1
GTTS-WQ3800MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ2913MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG827
GTTS-WQ3297MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ASN-1
GTTS-WQ2946MR IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ANB-011
GTTS-WQ14561MR IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA aCD1919
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW